Respiratory, Infectious Disease and Oncology
The Respiratory, Infectious Disease and Oncology (RIO) Clinical Trials Team conducts clinical trials of new drugs for patients with respiratory conditions such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), as well as respiratory infectious disease and lung cancer. The team also run clinical trials of new vaccines in healthy volunteers.
VAV00039 - a vaccine to protect against RSV
VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.
Assessment of airway clearance techniques in adults with bronchiectasis
Feasibility of Electrical Impedance Tomography in assessing short-term effects of airway clearance techniques in adults with bronchiectasis, an observational study.
ElevAAte - New Treatment for Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysems
Study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD Emphysema
EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1)
Nimble - Possible new medicine for Adults and Adolescents with Eosinophilic Asthma
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype.
PACIFIC-9
A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy.
Pilaster - New add on therapy to help treat chronic obstructive pulmonary disease with chronic bronchitis
Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis.
SNDX-6352-0506 - Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Axatilimab is a “monoclonal antibody”, which is an antibody manufactured in a laboratory. It is designed to specifically block a protein believed to be involved in lung fibrosis. By blocking this protein, Axatilimab may slow or stop the progression of IPF.
Whistle-PF a new oral treatment for patients with Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) or non-IPF Progressive Pulmonary Fibrosis (PPF)